1. Home
  2. GNPX vs SOPA Comparison

GNPX vs SOPA Comparison

Compare GNPX & SOPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$2.02

Market Cap

6.5M

Sector

Health Care

ML Signal

HOLD

Logo Society Pass Incorporated

SOPA

Society Pass Incorporated

HOLD

Current Price

$1.19

Market Cap

6.5M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
GNPX
SOPA
Founded
2009
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
6.5M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
GNPX
SOPA
Price
$2.02
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$22.50
AVG Volume (30 Days)
274.8K
861.8K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,227,427.00
Revenue This Year
N/A
$26.32
Revenue Next Year
N/A
$13.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.65
52 Week Low
$1.99
$0.64
52 Week High
$55.00
$6.75

Technical Indicators

Market Signals
Indicator
GNPX
SOPA
Relative Strength Index (RSI) 33.69 42.03
Support Level $2.51 $0.97
Resistance Level $3.68 $1.74
Average True Range (ATR) 0.29 0.21
MACD -0.09 0.01
Stochastic Oscillator 1.18 27.75

Price Performance

Historical Comparison
GNPX
SOPA

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SOPA Society Pass Incorporated

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.

Share on Social Networks: